Related Experiment Video
Updated: Feb 11, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
Published on: August 4, 2019
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Qiang Zhang1, Vladimir J N Bykov1, Klas G Wiman2
1Department of Oncology and Pathology, Cancer Center Karolinska (CCK), Karolinska Institutet, SE-17176, Stockholm, Sweden.
Abstract:
The TP53 tumor suppressor gene is frequently inactivated in human tumors by missense mutations in the DNA binding domain. TP53 mutations lead to protein unfolding, decreased thermostability and loss of DNA binding and transcription factor function. Pharmacological targeting of mutant p53 to restore its tumor suppressor function is a promising strategy for cancer therapy. The mutant p53 reactivating compound APR-246 (PRIMA-1Met) has been successfully tested in a phase I/IIa clinical trial. APR-246 is converted to the reactive electrophile methylene quinuclidinone (MQ), which binds covalently to p53 core domain. We identified cysteine 277 as a prime binding target for MQ in p53. Cys277 is also essential for MQ-mediated thermostabilization of wild-type, R175H and R273H mutant p53, while both Cys124 and Cys277 are required for APR-246-mediated functional restoration of R175H mutant p53 in living tumor cells. These findings may open opportunities for rational design of novel mutant p53-targeting compounds.
Insights
Researchers identified specific cysteine residues in the TP53 gene that are crucial targets for the cancer drug APR-246. This finding advances the development of new therapies to restore tumor suppressor function in cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The TP53 tumor suppressor gene is frequently inactivated in human cancers via missense mutations.
- TP53 mutations result in protein unfolding, reduced thermostability, and loss of DNA binding and transcription factor functions.
- Restoring tumor suppressor function of mutant p53 is a key strategy in cancer therapy.
Purpose of the Study:
- To identify the specific binding targets of the mutant p53 reactivating compound APR-246 (PRIMA-1Met).
- To elucidate the role of specific cysteine residues in APR-246-mediated p53 stabilization and functional restoration.
- To provide insights for the rational design of novel mutant p53-targeting cancer therapeutics.
Main Methods:
- In silico analysis to identify potential binding sites of APR-246's active metabolite, methylene quinuclidinone (MQ).
- Site-directed mutagenesis to assess the role of specific cysteine residues (Cys124, Cys277) in p53 function.
- Thermal shift assays to evaluate the thermostability of wild-type and mutant p53 proteins.
- Cell-based assays to measure the functional restoration of mutant p53 in cancer cells treated with APR-246.
Main Results:
- Cysteine 277 (Cys277) was identified as a primary binding target for MQ within the p53 core domain.
- Cys277 is essential for MQ-mediated thermostabilization of wild-type, R175H, and R273H mutant p53 proteins.
- Both Cys124 and Cys277 are required for APR-246-mediated functional restoration of the R175H mutant p53 in cellular models.
Conclusions:
- Cys277 is a critical residue for APR-246's mechanism of action, particularly in stabilizing p53.
- The combined involvement of Cys124 and Cys277 is necessary for restoring the tumor suppressor activity of specific mutant p53 forms.
- These findings support the development of targeted therapies aimed at reactivating mutant p53, offering new avenues for cancer treatment.
Related Concept Videos
Cross-reactivity
Reactivity of Enols
Reactivity of Enolate Ions
Radical Reactivity: Overview
Radical Reactivity: Nucleophilic Radicals
Radical Reactivity: Intramolecular vs Intermolecular

